Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2015 2
2016 3
2017 5
2018 6
2019 5
2020 6
2021 13
2022 13
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Overlapping features of therapy-related and de novo NPM1-mutated AML.
Othman J, Meggendorfer M, Tiacci E, Thiede C, Schlenk R, Dillon R, Stasik S, Venanzi A, Bertoli S, Delabesse E, Dumas PY, Pigneux A, Bidet A, Gilkes AF, Thomas I, Voso MT, Rambaldi A, Brunetti L, Perriello VM, Andresen V, Gjertsen BT, Martelli MP, Récher C, Röllig C, Bornhäuser M, Serve H, Müller-Tidow C, Baldus CD, Haferlach T, Russell N, Falini B. Othman J, et al. Among authors: dumas py. Blood. 2023 Apr 13;141(15):1846-1857. doi: 10.1182/blood.2022018108. Blood. 2023. PMID: 36508705 Free article.
Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.
Crinier A, Dumas PY, Escalière B, Piperoglou C, Gil L, Villacreces A, Vély F, Ivanovic Z, Milpied P, Narni-Mancinelli É, Vivier É. Crinier A, et al. Among authors: dumas py. Cell Mol Immunol. 2021 May;18(5):1290-1304. doi: 10.1038/s41423-020-00574-8. Epub 2020 Nov 25. Cell Mol Immunol. 2021. PMID: 33239726 Free PMC article.
[Management of AML in the elderly].
Dumas PY, Pigneux A. Dumas PY, et al. Bull Cancer. 2023 Apr;110(4):424-432. doi: 10.1016/j.bulcan.2023.02.005. Epub 2023 Mar 2. Bull Cancer. 2023. PMID: 36870810 Review. French.
AML consolidation therapy: timing matters.
Reimann AM, Schalk E, Jost F, Mougiakakos D, Weber D, Döhner H, Récher C, Dumas PY, Ditzhaus M, Fischer T, Sager S. Reimann AM, et al. Among authors: dumas py. J Cancer Res Clin Oncol. 2023 Nov;149(15):13811-13821. doi: 10.1007/s00432-023-05115-0. Epub 2023 Aug 3. J Cancer Res Clin Oncol. 2023. PMID: 37535164 Free PMC article.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: dumas py. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Peterlin P, Le Bris Y, Turlure P, Chevallier P, Ménard A, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Bouzy S, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Chevret S, Béné MC, Fenaux P. Peterlin P, et al. Among authors: dumas py. Lancet Haematol. 2023 Jul;10(7):e521-e529. doi: 10.1016/S2352-3026(23)00090-X. Epub 2023 May 25. Lancet Haematol. 2023. PMID: 37245522 Clinical Trial.
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Dumas PY, et al. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376378 Free article.
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
Belhadj M, Burroni B, Kosmider O, Willems L, Temple M, Bertoli S, Orvain C, Dumas PY, Berthon C, Gabellier L, Marcais A, Raffoux E, Pautas C, Genthon A, Decroocq J, Birsen R, Tamburini J, Bouscary D, Contejean A. Belhadj M, et al. Among authors: dumas py. Br J Haematol. 2023 Sep;202(6):e50-e53. doi: 10.1111/bjh.18961. Epub 2023 Jul 4. Br J Haematol. 2023. PMID: 37403204 No abstract available.
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L, Fenwarth L, Lambert J, de Botton S, Figeac M, Villenet C, Heiblig M, Dumas PY, Récher C, Berthon C, Lemasle E, Lebon D, Lambert J, Terré C, Celli-Lebras K, Dombret H, Preudhomme C, Cheok M, Itzykson R, Duployez N. Vasseur L, et al. Among authors: dumas py. Blood Adv. 2023 Aug 8;7(15):4024-4034. doi: 10.1182/bloodadvances.2023010155. Blood Adv. 2023. PMID: 37205853 Free PMC article.
61 results